Form 4: Singular Genomics CFO Dalen Meeter Reports Stock Transactions

Singular Genomics CFO Dalen Meeter acquired 500 shares of common stock through the settlement of vested Restricted Stock Units (RSUs) on November 9, 2024.

Summary

• Dalen Meeter, the Chief Financial Officer of Singular Genomics Systems, Inc., reported a transaction involving the company's stock.
• On November 9, 2024, Mr. Meeter acquired 500 shares of common stock.
• This acquisition resulted from the settlement of vested Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Singular Genomics common stock.
• Following the transaction, Mr. Meeter directly owns 8,693 shares of common stock.
• Additionally, Mr. Meeter holds 6,500 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction, which is neither particularly positive nor negative. It is a normal part of executive compensation.

Positives

• The acquisition of shares by the CFO could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It does not indicate any specific trend in the industry.

Comparison to Industry Standards

• Insider transactions are a normal part of operations for publicly listed companies.
• The vesting schedule of the RSUs, 16 equal quarterly installments over four years, is a common practice for employee equity compensation.
• Similar filings are made by executives at comparable companies such as Illumina, Pacific Biosciences, and Oxford Nanopore Technologies.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it is a routine vesting of stock options.

Key Dates

Keywords

Singular Genomics, Dalen Meeter, CFO, stock transaction, Restricted Stock Units, RSU, insider trading, share acquisition